Neurocrine Biosciences’s Licensing and Collaboration Agreement With Xenon Pharmaceuticals


Cooley LLP advised Neurocrine Biosciences on its licensing and collaboration agreement with Xenon Pharmaceuticals to develop first-in-class treatments for epilepsy.

Neurocrine will pay Xenon $50 million – $30 million upfront in cash and a $20 million equity investment – and up to $1.7 billion in additional development, regulatory and commercial milestone payments.

Under the agreement, Neurocrine gains an exclusive license to XEN901, a clinical-stage drug to treat pediatric patients with SCN8A developmental and epileptic encephalopathy and other forms of epilepsy, including focal epilepsy, as well as the rights to pre-clinical compounds under development to treat the disease. The agreement also includes a multi-year research collaboration to discover, identify and develop additional novel inhibitors.

Neurocrine, whose securities trade on the Nasdaq Global Select market under the symbol “NBIX,” is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.

Cooley lawyers Kay Chandler (Picture), Jason Kent and Rena Kaminsky led the team advising Neurocrine.

Involved fees earner: Megan Browdie – Cooley LLP; Kay Chandler – Cooley LLP; Rena Kaminsky – Cooley LLP; Jason Kent – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Neurocrine Biosciences, Inc.;

Author: Ambrogio Visconti